Progressive Degeneration of Human Mesencephalic Neuron-Derived Cells Triggered by Dopamine-Dependent Oxidative Stress Is Dependent on the Mixed-Lineage Kinase Pathway
暂无分享,去创建一个
Jeppe Falsig | Marcel Leist | Patrik Brundin | Johan van Beek | J. Falsig | P. Brundin | M. Leist | R. Dringen | J. Lotharius | J. van Beek | Ralf Dringen | Julie Lotharius | Sarah Payne | S. Payne
[1] F. Tietze. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. , 1969, Analytical biochemistry.
[2] D. Graham. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.
[3] G. Cohen,et al. Coupling of Dopamine Oxidation (Monoamine Oxidase Activity) to Glutathione Oxidation Via the Generation of Hydrogen Peroxide in Rat Brain Homogenates , 1981, Journal of neurochemistry.
[4] R. Guillery,et al. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain , 1982, Brain Research.
[5] L. Seiden,et al. Alpha-methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes , 1983, Brain Research.
[6] L. Seiden,et al. Increased dopamine metabolism in the rat neostriatum after toxic doses of d-methylamphetamine , 1983, Neuropharmacology.
[7] L. Seiden,et al. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers , 1984, Brain Research.
[8] C. J. Schmidt,et al. Role of dopamine in the neurotoxic effects of methamphetamine. , 1985, The Journal of pharmacology and experimental therapeutics.
[9] Seiden Ls. Methamphetamine: toxicity to dopaminergic neurons. , 1985 .
[10] L. Seiden. Methamphetamine: toxicity to dopaminergic neurons. , 1985, NIDA research monograph.
[11] R. Carelli,et al. Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats. , 1985, Research communications in chemical pathology and pharmacology.
[12] G. C. Wagner,et al. Methamphetamine-induced neuronal damage: A possible role for free radicals , 1989, Neuropharmacology.
[13] D. Sulzer,et al. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: A mechanism of action , 1990, Neuron.
[14] K. Jellinger,et al. Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis , 1992, Journal of neurochemistry.
[15] N. Neff,et al. K‐252a and Staurosporine Promote Choline Acetyltransferase Activity in Rat Spinal Cord Cultures , 1993, Journal of neurochemistry.
[16] K. Jellinger,et al. Neuromelanin and Nigrostriatal Dopamine Neuron Degeneration , 1993, Journal of Neurochemistry.
[17] C. Epstein,et al. Involvement of Oxygen‐based Radicals in Methamphetamine‐induced Neurotoxicity: Evidence from the Use of CuZnSOD Transgenic Mice a , 1994, Annals of the New York Academy of Sciences.
[18] J. Cambier,et al. Activation of phosphatidylinositol-3' kinase by Src-family kinase SH3 binding to the p85 subunit. , 1994, Science.
[19] D. Sulzer,et al. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[20] N. Neff,et al. K‐252a Induces Tyrosine Phosphorylation of the Focal Adhesion Kinase and Neurite Outgrowth in Human Neuroblastoma SH‐SY5Y Cells , 1995, Journal of neurochemistry.
[21] D. Sulzer,et al. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[22] C. Epstein,et al. AP‐1 DNA‐binding activation by methamphetamine involves oxidative stress , 1996, Synapse.
[23] E. Hall,et al. Treatment of mice with methamphetamine produces cell loss in the substantia nigra , 1996, Brain Research.
[24] D. Sulzer,et al. Reserpine inhibits amphetamine action in ventral midbrain culture. , 1996, Molecular pharmacology.
[25] R. Dringen,et al. Glutathione Content as an Indicator for the Presence of Metabolic Pathways of Amino Acids in Astroglial Cultures , 1996, Journal of neurochemistry.
[26] J. Cadet,et al. Methamphetamine induces apoptosis in immortalized neural cells: Protection by the Proto‐Oncogene, bcl‐2 , 1997, Synapse.
[27] G. Kroemer,et al. The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death , 1997, Oncogene.
[28] Y. Yamaoka,et al. Redox regulation of caspase-3(-like) protease activity: regulatory roles of thioredoxin and cytochrome c. , 1998, Journal of immunology.
[29] N. Neff,et al. Motoneuron Apoptosis Is Blocked by CEP-1347 (KT 7515), a Novel Inhibitor of the JNK Signaling Pathway , 1998, The Journal of Neuroscience.
[30] N. Neff,et al. CEP‐1347/KT7515, a JNK pathway inhibitor, supports the in vitro survival of chick embryonic neurons , 1998, Neuroreport.
[31] D. Sengelaub,et al. CEP-1347/KT7515 prevents motor neuronal programmed cell death and injury-induced dedifferentiation in vivo. , 1998, Journal of neurobiology.
[32] N. Neff,et al. Preservation of cholinergic activity and prevention of neuron death by CEP-1347/KT-7515 following excitotoxic injury of the nucleus basalis magnocellularis , 1998, Neuroscience.
[33] S. Kish,et al. Rat striatal levels of the antioxidant glutathione are decreased following binge administration of methamphetamine , 1998, Neuroscience Letters.
[34] M. Miller,et al. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. , 1999, The Journal of pharmacology and experimental therapeutics.
[35] N. Neff,et al. CEP‐1347 (KT7515), an Inhibitor of JNK Activation, Rescues Sympathetic Neurons and Neuronally Differentiated PC12 Cells from Death Evoked by three Distinct Insults , 1999, Journal of neurochemistry.
[36] R. Scott,et al. MPTP Activates c‐Jun NH2‐Terminal Kinase (JNK) and Its Upstream Regulatory Kinase MKK4 in Nigrostriatal Neurons In Vivo , 2000, Journal of neurochemistry.
[37] K. O’Malley,et al. The Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation , 2000, The Journal of Biological Chemistry.
[38] L. Greene,et al. CEP-1347 (KT7515), a Semisynthetic Inhibitor of the Mixed Lineage Kinase Family* , 2001, The Journal of Biological Chemistry.
[39] D. Bozyczko‐Coyne,et al. CEP‐1347/KT‐7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Aβ‐induced cortical neuron apoptosis , 2001, Journal of neurochemistry.
[40] L. Greene,et al. β‐Amyloid‐induced neuronal apoptosis requires c‐Jun N‐terminal kinase activation , 2001, Journal of neurochemistry.
[41] K. O’Malley,et al. Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity. , 2001, Annals of neurology.
[42] M. Leist,et al. In vivo and in vitro evidence for extracellular caspase activity released from apoptotic cells. , 2001, Biochemical and biophysical research communications.
[43] David Blum,et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease , 2001, Progress in Neurobiology.
[44] J. Uney,et al. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[45] β‐Amyloid‐induced neuronal apoptosis requires c‐Jun N‐terminal kinase activation , 2001, Journal of neurochemistry.
[46] G. Hanson,et al. A single methamphetamine administration rapidly decreases vesicular dopamine uptake. , 2002, The Journal of pharmacology and experimental therapeutics.
[47] D. Sulzer,et al. The neuromelanin of human substantia nigra and its interaction with metals , 2002, Journal of Neural Transmission.
[48] P. Brundin,et al. Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line* , 2002, The Journal of Biological Chemistry.
[49] A. Lin,et al. The true face of JNK activation in apoptosis , 2002, Aging cell.
[50] J. Cadet,et al. Mice with partial deficiency of c-Jun show attenuation of methamphetamine-induced neuronal apoptosis. , 2002, Molecular pharmacology.
[51] S. Gammeltoft,et al. Activation of the c‐Jun N Terminal Kinase Pathway in an Animal Model of Parkinson's Disease , 2002, Annals of the New York Academy of Sciences.
[52] Charles A. Harris,et al. Inhibition of the c-Jun N-Terminal Kinase Signaling Pathway by the Mixed Lineage Kinase Inhibitor CEP-1347 (KT7515) Preserves Metabolism and Growth of Trophic Factor-Deprived Neurons , 2002, The Journal of Neuroscience.
[53] D. Sulzer,et al. Methamphetamine-Induced Degeneration of Dopaminergic Neurons Involves Autophagy and Upregulation of Dopamine Synthesis , 2002, The Journal of Neuroscience.
[54] J. Yabut,et al. Glutathione depletion and oxidative stress. , 2002, Parkinsonism & related disorders.
[55] Philippe P Roux,et al. K252a and CEP1347 Are Neuroprotective Compounds That Inhibit Mixed-lineage Kinase-3 and Induce Activation of Akt and ERK* , 2002, The Journal of Biological Chemistry.
[56] Patrik Brundin,et al. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. , 2002, Nature reviews. Neuroscience.
[57] N. Barmack,et al. Vestibularly Evoked Climbing‐Fiber Responses Modulate Simple Spikes in Rabbit Cerebellar Purkinje Neurons , 2002, Annals of the New York Academy of Sciences.
[58] A. Maroney,et al. Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. , 2002, Progress in medicinal chemistry.
[59] S. Chung,et al. Methamphetamine-induced apoptosis in a CNS-derived catecholaminergic cell line. , 2002, Molecules and cells.
[60] J. Cadet,et al. Methamphetamine causes coordinate regulation of Src, Cas, Crk, and the Jun N-terminal kinase-Jun pathway. , 2002, Molecular pharmacology.
[61] J. Hirrlinger,et al. Glutathione Pathways in the Brain , 2003, Biological chemistry.
[62] R. Paules,et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. , 2003, Molecular cell.
[63] J. Andersen,et al. The Role of c‐Jun N‐Terminal Kinase (JNK) in Parkinson's Disease , 2003, IUBMB life.
[64] D. Sulzer,et al. Intracellular Patch Electrochemistry: Regulation of Cytosolic Catecholamines in Chromaffin Cells , 2003, The Journal of Neuroscience.
[65] Pasko Rakic,et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[66] Jeppe Falsig,et al. Specific Modulation of Astrocyte Inflammation by Inhibition of Mixed Lineage Kinases with CEP-13471 , 2004, The Journal of Immunology.
[67] Eugene M. Johnson,et al. Mixed-lineage kinases: a target for the prevention of neurodegeneration. , 2004, Annual review of pharmacology and toxicology.
[68] Ming-tao Li,et al. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson’s disease , 2004, Neuroscience Research.
[69] M. Leist,et al. Improvement of embryonic dopaminergic neurone survival in culture and after grafting into the striatum of hemiparkinsonian rats by CEP‐1347 , 2003, Journal of neurochemistry.
[70] J. Connor,et al. Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.